Improving aztreonam stewardship and cost through a penicillin allergy testing clinical guideline

Justin R. Chen, Scott A. Tarver, Kristin S. Alvarez, Wenjing Wei, David A. Khan

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background. Patients reporting penicillin allergy often receive unnecessary and costly broad-spectrum alternatives such as aztreonam with negative consequences. Penicillin allergy testing improves antimicrobial therapy but is not broadly used in hospitals due to insufficient testing resources and short-term expenses. We describe a clinical decision support (CDS) tool promoting pharmacist- administered penicillin allergy testing in patients receiving aztreonam and its benefits toward antimicrobial stewardship and costs. Methods. A CDS tool was incorporated into the electronic medical record, directing providers to order penicillin allergy testing for patients receiving aztreonam. An allergy-trained pharmacist reviewed orders placed through this new guideline and performed skin testing and oral challenges to determine whether these patients could safely take penicillin. Data on tests performed, antibiotic utilization, and cost-savings were compared with patients tested outside the new guideline as part of our institution's standard stewardship program. Results. The guideline significantly increased penicillin allergy testing among patients receiving aztreonam from 24% to 85% (P < .001) while reducing the median delay between admission and testing completion from 3.31 to 1.05 days (P = 0.008). Patients tested under the guideline saw a 58% increase in penicillin exposure (P = .046). Institutional aztreonam administration declined from 2.54 to 1.47 administrations per 1000 patient-days (P = .016). Average antibiotic costs per patient tested before and after CDS decreased from $1265.81 to $592.08 USD, a 53% savings. Conclusions. Targeting penicillin allergy testing to patients on aztreonam yields therapeutic and economic benefits during a single admission. This provides a cost-effective model for inpatient testing.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalOpen Forum Infectious Diseases
Volume5
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Aztreonam
Penicillins
Hypersensitivity
Guidelines
Costs and Cost Analysis
Clinical Decision Support Systems
Pharmacists
Anti-Bacterial Agents
Cost Savings
Electronic Health Records
Inpatients
Economics

Keywords

  • Aztreonam
  • Clinical decision support
  • Penicillin allergy
  • Skin test
  • Stewardship

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology

Cite this

Improving aztreonam stewardship and cost through a penicillin allergy testing clinical guideline. / Chen, Justin R.; Tarver, Scott A.; Alvarez, Kristin S.; Wei, Wenjing; Khan, David A.

In: Open Forum Infectious Diseases, Vol. 5, No. 6, 01.06.2018, p. 1-7.

Research output: Contribution to journalArticle

Chen, Justin R. ; Tarver, Scott A. ; Alvarez, Kristin S. ; Wei, Wenjing ; Khan, David A. / Improving aztreonam stewardship and cost through a penicillin allergy testing clinical guideline. In: Open Forum Infectious Diseases. 2018 ; Vol. 5, No. 6. pp. 1-7.
@article{d6968a54f51d425b91ad78e105e42ba0,
title = "Improving aztreonam stewardship and cost through a penicillin allergy testing clinical guideline",
abstract = "Background. Patients reporting penicillin allergy often receive unnecessary and costly broad-spectrum alternatives such as aztreonam with negative consequences. Penicillin allergy testing improves antimicrobial therapy but is not broadly used in hospitals due to insufficient testing resources and short-term expenses. We describe a clinical decision support (CDS) tool promoting pharmacist- administered penicillin allergy testing in patients receiving aztreonam and its benefits toward antimicrobial stewardship and costs. Methods. A CDS tool was incorporated into the electronic medical record, directing providers to order penicillin allergy testing for patients receiving aztreonam. An allergy-trained pharmacist reviewed orders placed through this new guideline and performed skin testing and oral challenges to determine whether these patients could safely take penicillin. Data on tests performed, antibiotic utilization, and cost-savings were compared with patients tested outside the new guideline as part of our institution's standard stewardship program. Results. The guideline significantly increased penicillin allergy testing among patients receiving aztreonam from 24{\%} to 85{\%} (P < .001) while reducing the median delay between admission and testing completion from 3.31 to 1.05 days (P = 0.008). Patients tested under the guideline saw a 58{\%} increase in penicillin exposure (P = .046). Institutional aztreonam administration declined from 2.54 to 1.47 administrations per 1000 patient-days (P = .016). Average antibiotic costs per patient tested before and after CDS decreased from $1265.81 to $592.08 USD, a 53{\%} savings. Conclusions. Targeting penicillin allergy testing to patients on aztreonam yields therapeutic and economic benefits during a single admission. This provides a cost-effective model for inpatient testing.",
keywords = "Aztreonam, Clinical decision support, Penicillin allergy, Skin test, Stewardship",
author = "Chen, {Justin R.} and Tarver, {Scott A.} and Alvarez, {Kristin S.} and Wenjing Wei and Khan, {David A.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1093/ofid/ofy106",
language = "English (US)",
volume = "5",
pages = "1--7",
journal = "Open Forum Infectious Diseases",
issn = "2328-8957",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Improving aztreonam stewardship and cost through a penicillin allergy testing clinical guideline

AU - Chen, Justin R.

AU - Tarver, Scott A.

AU - Alvarez, Kristin S.

AU - Wei, Wenjing

AU - Khan, David A.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background. Patients reporting penicillin allergy often receive unnecessary and costly broad-spectrum alternatives such as aztreonam with negative consequences. Penicillin allergy testing improves antimicrobial therapy but is not broadly used in hospitals due to insufficient testing resources and short-term expenses. We describe a clinical decision support (CDS) tool promoting pharmacist- administered penicillin allergy testing in patients receiving aztreonam and its benefits toward antimicrobial stewardship and costs. Methods. A CDS tool was incorporated into the electronic medical record, directing providers to order penicillin allergy testing for patients receiving aztreonam. An allergy-trained pharmacist reviewed orders placed through this new guideline and performed skin testing and oral challenges to determine whether these patients could safely take penicillin. Data on tests performed, antibiotic utilization, and cost-savings were compared with patients tested outside the new guideline as part of our institution's standard stewardship program. Results. The guideline significantly increased penicillin allergy testing among patients receiving aztreonam from 24% to 85% (P < .001) while reducing the median delay between admission and testing completion from 3.31 to 1.05 days (P = 0.008). Patients tested under the guideline saw a 58% increase in penicillin exposure (P = .046). Institutional aztreonam administration declined from 2.54 to 1.47 administrations per 1000 patient-days (P = .016). Average antibiotic costs per patient tested before and after CDS decreased from $1265.81 to $592.08 USD, a 53% savings. Conclusions. Targeting penicillin allergy testing to patients on aztreonam yields therapeutic and economic benefits during a single admission. This provides a cost-effective model for inpatient testing.

AB - Background. Patients reporting penicillin allergy often receive unnecessary and costly broad-spectrum alternatives such as aztreonam with negative consequences. Penicillin allergy testing improves antimicrobial therapy but is not broadly used in hospitals due to insufficient testing resources and short-term expenses. We describe a clinical decision support (CDS) tool promoting pharmacist- administered penicillin allergy testing in patients receiving aztreonam and its benefits toward antimicrobial stewardship and costs. Methods. A CDS tool was incorporated into the electronic medical record, directing providers to order penicillin allergy testing for patients receiving aztreonam. An allergy-trained pharmacist reviewed orders placed through this new guideline and performed skin testing and oral challenges to determine whether these patients could safely take penicillin. Data on tests performed, antibiotic utilization, and cost-savings were compared with patients tested outside the new guideline as part of our institution's standard stewardship program. Results. The guideline significantly increased penicillin allergy testing among patients receiving aztreonam from 24% to 85% (P < .001) while reducing the median delay between admission and testing completion from 3.31 to 1.05 days (P = 0.008). Patients tested under the guideline saw a 58% increase in penicillin exposure (P = .046). Institutional aztreonam administration declined from 2.54 to 1.47 administrations per 1000 patient-days (P = .016). Average antibiotic costs per patient tested before and after CDS decreased from $1265.81 to $592.08 USD, a 53% savings. Conclusions. Targeting penicillin allergy testing to patients on aztreonam yields therapeutic and economic benefits during a single admission. This provides a cost-effective model for inpatient testing.

KW - Aztreonam

KW - Clinical decision support

KW - Penicillin allergy

KW - Skin test

KW - Stewardship

UR - http://www.scopus.com/inward/record.url?scp=85048568569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048568569&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofy106

DO - 10.1093/ofid/ofy106

M3 - Article

C2 - 29977963

AN - SCOPUS:85048568569

VL - 5

SP - 1

EP - 7

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

SN - 2328-8957

IS - 6

ER -